Interferon-lambda and therapy for chronic hepatitis C virus infection
- 5 August 2011
- journal article
- review article
- Published by Elsevier in Trends in Immunology
- Vol. 32 (9), 443-450
- https://doi.org/10.1016/j.it.2011.07.002
Abstract
No abstract availableKeywords
This publication has 63 references indexed in Scilit:
- Phase 1b Study of Pegylated Interferon Lambda 1 With or Without Ribavirin in Patients with Chronic Genotype 1 Hepatitis C Virus Infection†Hepatology, 2010
- Interferon-Lambda: A New Addition to an Old FamilyJournal of Interferon & Cytokine Research, 2010
- Preclinical and Clinical Development of Pegylated Interferon-Lambda 1 in Chronic Hepatitis CJournal of Interferon & Cytokine Research, 2010
- Pegylated interferons α2a and α2b in the treatment of chronic hepatitis CNature Reviews Gastroenterology & Hepatology, 2010
- Interferon Lambda as a Potential New Therapeutic for Hepatitis CAnnals of the New York Academy of Sciences, 2009
- Type I Interferon Receptors: Biochemistry and Biological FunctionsJournal of Biological Chemistry, 2007
- IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complexNature Immunology, 2002
- IL-28, IL-29 and their class II cytokine receptor IL-28RNature Immunology, 2002
- A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses.Proceedings of the National Academy of Sciences, 1995
- Functional Role of Type I and Type II Interferons in Antiviral DefenseScience, 1994